← Praram 9 Hospital overview

Praram 9 Hospital vs Fresenius SE & Co. KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Praram 9 Hospital Public Company Limited (PR9.BK)

Q3 2026
▲3▼1

PR9.BK Q3 2026: Foreign patient rebound and high-margin cases drive profit upcycle

  • Foreign patient recovery Revenue from Myanmar patients jumped 55.8%, and Middle East patients also increased, fueling a profit upcycle. This rebound in foreign demand is a key growth driver for the hospital.

    It directly explains the main source of revenue growth and profit recovery.

  • Shift to complex cases The hospital is focusing more on high-margin complex treatments like kidney, heart, and brain specialties. This mix improvement boosts profitability beyond just patient volume growth.

    It highlights a strategic shift that enhances margins and overall profitability.

  • Broker upgrades and record profit forecast Brokers raised target prices to 22–24.50 baht, expecting record Q3 profit up 11% YoY and 31% QoQ. Flu/COVID cases, new equipment, dialysis expansion, and tighter GLP-1 rules also support growth.

    It captures analyst optimism and specific operational catalysts driving the stock.

  • Foreign patient reliance and modest growth Heavy reliance on foreign patients (Middle East ~10% of revenue) makes results vulnerable to geopolitical or tourism shifts. Growth targets remain mid-single-digit, and broker optimism may already be priced in.

    It presents the main risks and counterweight to the positive outlook.

August 2026
▲4

PR9's foreign-patient recovery and high-margin complex cases drive profit upcycle

  • Foreign patient recovery and complex cases lift profit PR9's Q2 profit rose 1.3% to 184 million baht, with Myanmar revenue up 55.8% to a record. July revenue improved from Thai and foreign patients, especially Myanmar and Middle East. The hospital expects a stronger second half, targeting mid-single-digit revenue growth for 2026.

    Shows the core earnings recovery and patient trends that directly support the stock.

  • Brokers raise targets on high-margin strategy Phillip Securities set a 24 baht target, citing PR9's shift to kidney, heart and brain specialties, new equipment, and ICU/CCU/Neuro bed expansion from 24 to 31 beds in Q4 2026. Krungsri also picked PR9 as a top stock with a 24 baht target.

    Higher broker targets and the complex-disease strategy are key reasons investors are buying PR9 now.

  • Q3 profit expected to jump on foreign patients and flu CGSI expects PR9's Q3 2026 net profit to rise 11% year on year and 31% quarter on quarter, driven by more foreign patients and influenza/COVID-19 cases. Asia Plus sees Middle Eastern tourist arrivals up 12.9% year on year in Q3, with PR9's Middle East exposure about 10% of revenue.

    Directly explains the expected Q3 profit surge that is driving the stock.

  • Flood impact limited, telemedicine keeps patients PR9 used telemedicine and ambulances during Bangkok floods, keeping bed occupancy at 70% and foreign patients from the Middle East, Myanmar and China coming in. Maybank says PR9 has no beds in flood-affected areas, so the 2026 profit hit is only 0.6-0.7%.

    Shows the flood is not a major threat, removing a potential negative for the stock.

Latest
▲4

PR9's foreign-patient recovery and high-margin complex cases drive profit upcycle

  • Foreign patient recovery and complex cases lift profit PR9's Q2 profit rose 1.3% to 184 million baht, with Myanmar revenue up 55.8% to a record. July revenue improved from Thai and foreign patients, especially Myanmar and Middle East. The hospital expects a stronger second half, targeting mid-single-digit revenue growth for 2026.

    Shows the core earnings recovery and patient trends that directly support the stock.

  • Brokers raise targets on high-margin strategy Phillip Securities set a 24 baht target, citing PR9's shift to kidney, heart and brain specialties, new equipment, and ICU/CCU/Neuro bed expansion from 24 to 31 beds in Q4 2026. Krungsri also picked PR9 as a top stock with a 24 baht target.

    Higher broker targets and the complex-disease strategy are key reasons investors are buying PR9 now.

  • Q3 profit expected to jump on foreign patients and flu CGSI expects PR9's Q3 2026 net profit to rise 11% year on year and 31% quarter on quarter, driven by more foreign patients and influenza/COVID-19 cases. Asia Plus sees Middle Eastern tourist arrivals up 12.9% year on year in Q3, with PR9's Middle East exposure about 10% of revenue.

    Directly explains the expected Q3 profit surge that is driving the stock.

  • Flood impact limited, telemedicine keeps patients PR9 used telemedicine and ambulances during Bangkok floods, keeping bed occupancy at 70% and foreign patients from the Middle East, Myanmar and China coming in. Maybank says PR9 has no beds in flood-affected areas, so the 2026 profit hit is only 0.6-0.7%.

    Shows the flood is not a major threat, removing a potential negative for the stock.

September 2026
▲4

PR9 gains on foreign patients, record Q3 profit forecast, defensive appeal

  • Foreign patient growth supports revenue target Foreign patient growth, especially from the Middle East and Myanmar, supports PR9's 2026 revenue target. This is a key driver because it directly boosts hospital revenue and is a core part of the growth story.

    Foreign patient growth is a fundamental demand driver for PR9's revenue.

  • Brokers forecast record Q3 profit and raise targets Brokers forecast a record Q3 profit and raised their price targets to 22–24.50 baht. This reflects increased optimism and can drive the stock price higher as investors react to analyst upgrades.

    Broker upgrades and profit forecasts directly influence investor sentiment and price targets.

  • New equipment and dialysis centre lift higher-margin cases New equipment and a near-full dialysis centre should lift higher-margin complex cases. This improves profitability by attracting more complex, higher-revenue procedures.

    Operational improvements can enhance margins and profitability.

  • Tighter FDA rules on GLP-1 drugs may benefit hospitals Tighter FDA rules on GLP-1 drugs may push users to hospitals, benefiting PR9. This regulatory change could increase patient volumes for weight-management and related services.

    Regulatory shifts can redirect patient flow to hospitals, boosting demand.

▲4

Brokers boost PR9 targets as hospital sector turns upcycle

  • KKPS raises PR9 target to 24.50 baht on sector overweight KKPS upgraded the hospital sector to overweight and set a 24.50 baht target for PR9, expecting the state to shift more public health costs to private hospitals. A higher target from a major broker pulls the share price up as investors price in more future profit.

    A new, higher broker target directly raises the price investors are willing to pay for PR9.

  • CGSI sees Q3 profit up 11% and names PR9 a top pick CGSI expects PR9's Q3 2026 net profit to rise 11% from a year earlier and 35% from the prior quarter to 248 million baht, naming it a top pick. A stronger profit forecast supports the share price because investors pay for future earnings.

    A fresh profit forecast and top-pick status are new reasons for investors to buy PR9.

  • Tighter FDA rules on GLP-1 drugs shift users to hospitals Thailand's FDA now classifies GLP-1 weight-loss drugs as specially controlled, pushing users toward hospitals for prescriptions and monitoring. Asia Plus sees PR9 as a standout beneficiary thanks to its cash-paying patients and specialized services, with a 23 baht target.

    This new regulation creates a fresh source of patient visits and revenue for PR9.

  • PR9 named a top Q4 pick and defensive stock amid foreign selling InnovestX picked PR9 as a top stock for Q4 2026, and Asia Plus listed it among low-volatility healthcare names resilient to heavy foreign selling. Being chosen as a safe place to park money can support the share price even when the overall market falls.

    New top-pick and defensive designations attract buying interest that supports PR9's price.

▲4

PR9's foreign-patient growth and record Q3 profit forecast drive the stock

  • Foreign patient growth supports 2026 revenue target PR9 said Q3 2026 is growing on more foreign patients, especially from the Middle East and Myanmar, plus returning Thai patients. Foreign patients are about 27% of the total. Management is confident 2026 revenue will grow by a single-digit percentage as planned. More patients means more revenue, which supports the share price.

    This is the company's own update on the demand driving its revenue, the core reason the stock is moving.

  • Broker forecasts record Q3 profit and a 22 baht target Bualuang expects PR9 to post a record Q3 2026 core profit of 237 million baht, up 7% from a year earlier and 29% from the prior quarter, on revenue of 1.44 billion baht. It keeps a Buy rating and 22 baht target price, seeing a new profit upcycle.

    A record profit forecast and higher target price directly shape what investors expect the stock to be worth.

  • New equipment and dialysis centre lift higher-margin cases The dialysis centre is running near full capacity, and new equipment such as Bi-plane Angiography, Hyperbaric Oxygen Therapy and a Neuro ICU should raise the share of higher-margin complex cases from Q4 2026. Richer case mix lifts profit per patient, supporting the stock.

    This explains the operational change behind the expected profit growth, not just the headline number.

  • Brokers name PR9 a defensive pick ahead of the Fed meeting Several brokers put PR9 in defensive value and domestic-play lists, citing steady hospital revenue and benefit from a weaker baht, while tech stocks face pressure and markets worry about a possible Fed rate hike. Defensive buying can support the share price even in a shaky market.

    It shows the outside market forces pushing money toward PR9 right now, a real driver of demand for the stock.

Fresenius SE & Co. KGaA (FRE.XETRA)